Skip to the record

Swiss capital increases, read from the official gazette and scored for financing rounds.

updated every weekdayrelease r10data as of 8 Oct 2026

↺ Try a rewind: Soverli AG on 24 Sep 2025, 83 days before the round was announced

Release evaluation · 7 Oct 2026 · does not rewind · rules + Claude: precision 2%–100% (n=17), recall 16/30 announced rounds · rules-only: precision 1%–99% (n=29), recall 18/30 announced rounds · Methodology

Published by 7 Jun 2026

Drag the red line through time · ← → a day · Shift+← → a week. Later days aren’t drawn: they haven’t been published yet.

Scope · likely financings by canton

43 likely financings · 9 May 2026 – 7 Jun 2026 · the feed below shows one weekZH ✕ show all cantonsMap: Natural Earth

Likely financing: Looks like new money from outside investors: Claude, reading the entry and the rule signals, scores it 0.60 or higher.
Undecided: Some financing signals, not enough to call it: a score from 0.35 to below 0.60, or no usable score.
Capital increased: No sign of a financing round: the pre-filter found nothing to send to Claude, or Claude scored it below 0.35. Typical causes are converted loans, assets contributed in kind, reserves turned into capital or a conversion to an AG.
Confirmed round: A financing announcement on startupticker.ch names the company and matches this increase.

Published 1–7 Jun 2026 · canton ZH

15 capital increases · 5 shown

Capital increases published 1–7 Jun 2026
Company	Status	Nominal share capital (CHF) before → after	New shares, % of post-step shares	Announced roundnot disclosed in the SHAB	SHAB published	Source
Virtamed AGZH · Die Gesellschaft bezweckt die Forschung, Entwicklung, Herstellung und den Vertrieb von Trainings- und …SHAB publication HR02-1006667025	Likely financingscore 0.75	383’435 → 1’120’746New shares 65.8%	65.8%	—	4 Jun 2026	SHAB publication HR02-1006667025
OphthaNova Therapeutics AGZH · Die Gesellschaft bezweckt die Entwicklung von biopharmazeutischen Produkten, insbesondere im Bereich der …SHAB publication HR02-1006666975	Likely financingscore 0.85	100’000 → 111’525.40New shares — nominal value per share changed	— nominal value per share changed	—	4 Jun 2026	SHAB publication HR02-1006666975
dimpora AGZH · Die Gesellschaft bezweckt die Entwicklung, die Herstellung und den Vertrieb von Membranen und deren Produkten …SHAB publication HR02-1006666898	Likely financingscore 0.65	173’225 → 193’205New shares 10.3%	10.3%	—	4 Jun 2026	SHAB publication HR02-1006666898
UniSieve AGZH · Die Gesellschaft bezweckt die Entwicklung, Herstellung und den Handel mit porösen Materialien sowie die …SHAB publication HR02-1006664330	Likely financingscore 0.93	176’164 → 230’821New shares 23.7%	23.7%	—	2 Jun 2026	SHAB publication HR02-1006664330
Aderis AGZH · Die Gesellschaft bezweckt die Entwicklung, den Betrieb, den Vertrieb sowie die Vermarktung von Software, …SHAB publication HR02-1006662834	Likely financingscore 0.93	100’000 → 124’121.10New shares 19.4%	19.4%	—	1 Jun 2026	SHAB publication HR02-1006662834

10 other capital increases published this week ▸